



## **ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017**

January 3, 2017

SAN DIEGO--(BUSINESS WIRE)--Jan. 3, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 35<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017, at 1:30 pm Pacific Time in San Francisco.

A live webcast of ACADIA's presentation will be accessible on the company's website, [www.acadia-pharm.com](http://www.acadia-pharm.com), under the investors section and an archived recording will be available on the website through January 24, 2017.

### *About ACADIA Pharmaceuticals*

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA maintains a website at [www.acadia-pharm.com](http://www.acadia-pharm.com) to which we regularly post copies of our press releases as well as additional information and through which interested parties can subscribe to receive e-mail alerts.

### *Forward-Looking Statements*

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA's drug discovery and development programs, and the benefits to be derived from NUPLAZID® (pimavanserin) and ACADIA's product candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development, approval and commercialization, and in collaborations with others, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2015 as well as ACADIA's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170103005347/en/>

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.  
Lisa Barthelemy, Investor Relations  
(858) 558-2871  
[ir@acadia-pharm.com](mailto:ir@acadia-pharm.com)